MLN-519. Millennium/PAION.
Millennium Pharmaceuticals Inc (formerly LeukoSite Inc) and PAION GmbH are developing MLN-519, a ubiquitin/proteasome enzyme inhibitor, for the potential treatment of inflammatory diseases and stroke. MLN-519 is currently undergoing phase I clinical trials in acute stroke and myocardial infarction, and is poised to enter phase II trials.
Neurological Section, SMDN-Center for Cardiovascular Medicine, 41 Via Trento, I-67039-Sulmona, AQ, Italy. mariodinapoli@katamail.com
Mario
M
Di Napoli
Francesca
F
Papa
D000111:Acetylcysteine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003546:Cysteine Endopeptidases; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors; D009203:Myocardial Infarction / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex; D020521:Stroke / Q000188:drug therapy; D025801:Ubiquitin / Q000037:antagonists & inhibitors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D018696:Neuroprotective Agents; C411422:PS519; D025801:Ubiquitin; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D000111:Acetylcysteine